BioSpace News Archive

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference.

Boston Immune Technologies and Therapeutics, Inc., a privately held developer of novel tumor necrosis factor superfamily receptor antagonist antibodies, announced that the company will be presenting new data from its CD40 program at Immunology2023, the annual meeting of the American Association of Immunologists.

Cabaletta Bio, Inc. announced that Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio, will deliver an invited, oral presentation titled “CD 19 CAR T-cells for SLE” as part of the session titled “Immune Effector Cells: 2023 and Beyond!” on Tuesday, May 16, 2023, at 11:05 a.m.

Cellectis today announced that it will present clinical data on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were presented in an oral presentation at the 64th American Society of Hematology (ASH) annual meeting, as well as preclinical data on multiplex engineering for superior generation of CAR T-cells, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA.

NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (“NK”) cell therapeutics, today announced an upcoming presentation on its NK cell therapy (SNK01) at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

Sana Biotechnology, Inc. (NASDAQ: SANA) today announced that six abstracts highlighting preclinical data from the fusogen platform have been accepted for presentation, including two oral presentations, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that six data presentations, including two oral presentations, highlighting the Company’s preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employee’s acceptance of employment with the company.

Aquestive Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments in its business.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26th ASGCT Annual Meeting being held May 16-20, 2023, in-person in Los Angeles, CA and in a virtual format.